Outcomes of radiosensitisation in elderly patients with advanced bladder cancer.
dc.contributor.author | Christodoulou, Marianna | |
dc.contributor.author | Reeves, K | |
dc.contributor.author | Hodgson, Clare | |
dc.contributor.author | Zeniou, A | |
dc.contributor.author | Slevin, F | |
dc.contributor.author | Kennedy, J | |
dc.contributor.author | Hoskin, P | |
dc.contributor.author | Henry, A | |
dc.contributor.author | Choudhury, Ananya | |
dc.date.accessioned | 2018-06-30T14:11:11Z | |
dc.date.available | 2018-06-30T14:11:11Z | |
dc.date.issued | 2018-06-02 | |
dc.identifier.citation | Outcomes of radiosensitisation in elderly patients with advanced bladder cancer. 2018, Radiother Oncol | en |
dc.identifier.issn | 1879-0887 | |
dc.identifier.pmid | 29871812 | |
dc.identifier.doi | 10.1016/j.radonc.2018.05.022 | |
dc.identifier.uri | http://hdl.handle.net/10541/621080 | |
dc.description.abstract | There is little evidence to guide treatment in elderly patients with muscle invasive bladder cancer (MIBC). We evaluated the efficacy and tolerability of concurrent radical radiotherapy with gemcitabine radiosensitisation (GemX) in elderly patients with MIBC and compared outcomes to those from the bladder carbogen and nicotinamide (BCON) phase III trial. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | en |
dc.title | Outcomes of radiosensitisation in elderly patients with advanced bladder cancer. | en |
dc.type | Article | en |
dc.contributor.department | Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, United Kingdom | en |
dc.identifier.journal | Radiotherapy and Oncology | en |
html.description.abstract | There is little evidence to guide treatment in elderly patients with muscle invasive bladder cancer (MIBC). We evaluated the efficacy and tolerability of concurrent radical radiotherapy with gemcitabine radiosensitisation (GemX) in elderly patients with MIBC and compared outcomes to those from the bladder carbogen and nicotinamide (BCON) phase III trial. |